• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Current Indications for Stenting: Symptoms or Survival .支架置入的当前适应证:症状或生存
Methodist Debakey Cardiovasc J. 2018 Jan-Mar;14(1):7-13. doi: 10.14797/mdcj-14-1-7.
2
Left Main Stenting in Comparison With Surgical Revascularization: 10-Year Outcomes of the (Left Main Coronary Artery Stenting) LE MANS Trial.左主干支架置入术与外科血运重建术的比较:(左主干冠状动脉支架置入术)勒芒试验的10年结果
JACC Cardiovasc Interv. 2016 Feb 22;9(4):318-327. doi: 10.1016/j.jcin.2015.10.044.
3
Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease: An External Validation of the SYNTAX Score II Model in the 1,480 Patients of the BEST and PRECOMBAT Randomized Controlled Trials.多支血管病变和/或无保护左主干病变患者行冠状动脉支架置入术或旁路移植术的个体长期死亡率预测:SYNTAX II 评分模型在 BEST 和 PRECOMBAT 随机对照试验 1480 例患者中的外部验证。
JACC Cardiovasc Interv. 2016 Aug 8;9(15):1564-72. doi: 10.1016/j.jcin.2016.04.023.
4
Revascularization in stable coronary disease: evidence and uncertainties.稳定型冠状动脉疾病的血运重建:证据与不确定性。
Nat Rev Cardiol. 2018 Jul;15(7):408-419. doi: 10.1038/s41569-018-0006-z.
5
Mechanical Circulatory Support in High-Risk Percutaneous Coronary Intervention.高危经皮冠状动脉介入治疗中的机械循环支持
Methodist Debakey Cardiovasc J. 2018 Jan-Mar;14(1):23-31. doi: 10.14797/mdcj-14-1-23.
6
The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.基于解剖和临床的 NERS(新风险分层)评分 II 预测无保护左主干冠状动脉疾病支架置入后的临床结局:来自多中心、前瞻性登记研究的结果。
JACC Cardiovasc Interv. 2013 Dec;6(12):1233-41. doi: 10.1016/j.jcin.2013.08.006. Epub 2013 Nov 13.
7
Preventive stenting in acute myocardial infarction.急性心肌梗死的预防性支架置入术。
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):131-138. doi: 10.1016/j.jcin.2014.09.006. Epub 2014 Oct 31.
8
Stent for Life: how this initiative began?支架为生命:这个倡议是如何开始的?
EuroIntervention. 2012 Aug;8 Suppl P:P8-10. doi: 10.4244/EIJV8SPA3.
9
Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?用于治疗冠状动脉疾病的生物可吸收血管支架:我们从随机对照临床试验中学到了什么?
Coron Artery Dis. 2017 Jan;28(1):77-89. doi: 10.1097/MCA.0000000000000414.
10
Delayed versus immediate stenting for the treatment of ST-elevation acute myocardial infarction with a high thrombus burden.延迟支架置入与即刻支架置入治疗高血栓负荷ST段抬高型急性心肌梗死的对比研究
Coron Artery Dis. 2012 Nov;23(7):497-506. doi: 10.1097/MCA.0b013e328358a5ad.

本文引用的文献

1
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.稳定型心绞痛患者的经皮冠状动脉介入治疗(ORBITA):一项双盲、随机对照试验。
Lancet. 2018 Jan 6;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9. Epub 2017 Nov 2.
2
β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.急性心肌梗死后无心力衰竭或心室功能障碍患者使用β受体阻滞剂与死亡率的关系
J Am Coll Cardiol. 2017 Jun 6;69(22):2710-2720. doi: 10.1016/j.jacc.2017.03.578.
3
Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease.三血管病变或左主干病变患者接受手术或 DES 治疗后的生活质量。
J Am Coll Cardiol. 2017 Apr 25;69(16):2039-2050. doi: 10.1016/j.jacc.2017.02.031.
4
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗1年后双联抗血小板治疗获益与风险预测规则的制定与验证
JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775.
5
Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial.在TERISA临床试验中西雅图心绞痛问卷与每日心绞痛日记的比较。
Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):844-50. doi: 10.1161/CIRCOUTCOMES.113.000752. Epub 2014 Sep 23.
6
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial.尽管进行了最佳治疗,但冠状动脉解剖结构和左心室射血分数对预后的重要性:在临床结果利用血运重建和强化药物评估试验中评估残余风险。
Am Heart J. 2013 Sep;166(3):481-7. doi: 10.1016/j.ahj.2013.07.007. Epub 2013 Aug 2.
7
Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.在“利用血运重建和积极药物评估的临床结果”(COURAGE)试验中,随机接受最佳药物治疗的患者在12个月内交叉接受血运重建治疗的频率、预测因素及后果。
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):409-18. doi: 10.1161/CIRCOUTCOMES.113.000139. Epub 2013 Jul 9.
8
Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status.急性心肌梗死后双联抗血小板治疗致出血性不良反应及其对健康状况的影响。
J Am Coll Cardiol. 2013 May 28;61(21):2130-8. doi: 10.1016/j.jacc.2013.02.044. Epub 2013 Mar 26.
9
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).评价雷诺嗪在 2 型糖尿病合并慢性稳定型心绞痛患者中的疗效:TERISA 随机临床试验结果(慢性稳定型心绞痛患者中雷诺嗪对 2 型糖尿病的评价)。
J Am Coll Cardiol. 2013 May 21;61(20):2038-45. doi: 10.1016/j.jacc.2013.02.011. Epub 2013 Mar 10.
10
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.《2013年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2013 Jan 1;127(1):e6-e245. doi: 10.1161/CIR.0b013e31828124ad. Epub 2012 Dec 12.

支架置入的当前适应证:症状或生存

Current Indications for Stenting: Symptoms or Survival .

作者信息

Arnold Suzanne V

机构信息

SAINT LUKE'S MID AMERICA HEART INSTITUTE, UNIVERSITY OF MISSOURI-KANSAS CITY, KANSAS CITY, MISSOURI.

出版信息

Methodist Debakey Cardiovasc J. 2018 Jan-Mar;14(1):7-13. doi: 10.14797/mdcj-14-1-7.

DOI:10.14797/mdcj-14-1-7
PMID:29623167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5880567/
Abstract

The major goals of treating ischemic heart disease are to reduce angina, improve quality of life, and ultimately reduce mortality. While medical therapy can effectively address these aims, there is still much research and debate about the role of percutaneous coronary intervention in the treatment spectrum-specifically, whether or not stenting prolongs life or simply treats symptoms without impacting survival. The data supporting revascularization for survival benefit came from patients who underwent bypass graft surgery prior to the introduction of effective medical management. Although both physicians and patients continue to believe in the life-saving ability of coronary stenting, little data exist to support this belief outside of when used during an acute myocardial infarction. Strategy trials designed to test the benefit of coronary stenting have limitations that have curbed physicians' willingness to accept the results, but they provide the best evidence for how to optimally manage these patients. In this article, we explore the data supporting the use of coronary stenting for various indications and the questions that remain to be answered.

摘要

治疗缺血性心脏病的主要目标是减轻心绞痛、改善生活质量并最终降低死亡率。虽然药物治疗能够有效实现这些目标,但关于经皮冠状动脉介入治疗在整个治疗体系中的作用,仍存在大量研究和争议——具体而言,支架置入术究竟是能延长生命,还是仅仅缓解症状而不影响生存率。支持血管重建以获得生存获益的数据来自于在有效药物治疗出现之前接受搭桥手术的患者。尽管医生和患者仍然相信冠状动脉支架置入术具有挽救生命的能力,但除了在急性心肌梗死期间使用外,几乎没有数据支持这一观点。旨在测试冠状动脉支架置入术益处的策略试验存在局限性,这抑制了医生接受试验结果的意愿,但它们为如何最佳管理这些患者提供了最好的证据。在本文中,我们探讨了支持冠状动脉支架置入术用于各种适应症的数据以及仍有待解答的问题。